MADIT ASIA Cardiac Resynchronization Trial (MADIT-ASIA)
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Congestive Heart Failure
- Sponsor
- Boston Scientific Corporation
- Enrollment
- 1
- Locations
- 21
- Primary Endpoint
- Primary Endpoint
- Status
- Terminated
- Last Updated
- 12 years ago
Overview
Brief Summary
The purpose of this trial or study is to determine if pacemaker therapy can be a beneficial alternative to conventional medical therapy in patients with a history of moderate heart failure. The investigators are looking to enroll approximately 180 people in this trial. Patients will be randomized in two groups. One group will be implanted with a pacemaker and will continue to receive conventional medical therapy as prescribed by their doctor. The second group will continue to receive conventional medical therapy as prescribed by their doctor and will not be implanted with a pacemaker. Clinical histories, physical exams, and external device testing will be collected both at the time of enrollment in the trial and during follow-up study visits. Patients who enter the study will be seen for study visits at 1 month, 3 and 6 months.
Detailed Description
MADIT-ASIA is a multicenter, prospective, randomized clinical study. The primary aim is to show that two lead CRT-P with guideline-based optimal pharmacological therapy is associated with a significantly greater improvement in left ventricular ejection fraction (LVEF) at 6 months compared with guideline-based optimal pharmacologic therapy only. The study will be initially conducted at approximately 25 centers in up to 9 countries in Asia including India, Thailand, Taiwan, Malaysia, China, Japan, South Korea and Singapore. If necessary, more sites may be invited to participate to meet the enrollment goal. Following randomization, subjects will have scheduled clinic visit follow-ups at 1, 3 and 6-month intervals. Relevant event history, cardiac medications, physical assessment, device interrogation/programming status and adverse events will be collected at each follow-up visit. At the 6-month visit, a repeat echocardiogram and a 12-lead ECG will be obtained. Subjects will be followed through the 6 month visit. After that, subjects will have a safety follow up contact at the end of the study. The study will end when the last randomized subject reaches the 6 months visit.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject is age 18 or above, or of legal age to give informed consent specific to state and national law
- •Hospitalization for heart failure using the Framingham criteria requiring medical treatment more than 4 weeks ago but less than six months prior to randomization date
- •Subject in sinus rhythm
- •Subject with QRS duration \>110 milliseconds and left bundle branch block or incomplete left bundle branch block
- •Subject with ejection fraction 36-50%
- •Subject with ischemic or non-ischemic heart disease
- •Subject on stable\* optimal pharmacologic therapy for the cardiac condition that is guideline-based and may include one or more of the following medications: Loop diuretics (e.g., furosemide, bumetanide, torsemide) unless the subject is not indicated, is contraindicated, or is intolerant of loop diuretics; Angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) unless the subject failed, is not indicated, or is contraindicated for these therapies; Aldosterone antagonists unless the subject is not indicated, or is intolerant of aldosterone antagonists; Beta-blockers unless the subject is not indicated, contraindicated, or is intolerant of beta-blockers. The choice of selective or non-selective beta-blockers use is left to the Investigator's discretion \* For purposes of the study, "stable" is defined as beta blockers and ACE/ARB for at least three months prior to randomization, unless contraindicated or not tolerated, with stable doses for at least one month prior to randomization. It is permissible for diuretic and aldosterone antagonist dosage to have been adjusted as necessary.
Exclusion Criteria
- •Subject with a currently implanted pacemaker, ICD, CRT-P or CRT-D generator or device component
- •Subject with a history of spontaneous sustained VT\>160 bpm or VF
- •Subject with permanent or chronic AF, or cardioversion for AF within the past 3 calendar months before randomization
- •Subject with structural heart disease such as congenital heart disease, valvular heart disease, e.g., rheumatic valvular heart disease, amyloid heart disease, etc.
- •Subject with coronary artery bypass graft surgery or percutaneous coronary intervention within the past 3 calendar months before randomization
- •Subject with enzyme positive myocardial infarction within the past 3 calendar months prior to randomization
- •Subject with angiographic evidence of coronary disease who are candidates for coronary revascularization and are likely to undergo coronary artery bypass graft surgery or percutaneous coronary intervention in the foreseeable future
- •Right bundle branch block or non-specific interventricular conduction delay
- •Subject with second or third degree heart block
- •Subject in New York Heart Association Class IV (symptoms of heart failure at rest)
Outcomes
Primary Outcomes
Primary Endpoint
Time Frame: 6 months post randomization
The primary endpoint will be the change in left ventricular ejection fraction (LVEF) from baseline to six months.
Secondary Outcomes
- Atrial fibrillation events(6 months post randomization)
- Change in left atrial size(6 months post randomization)
- Recurrent heart failure or cardiovascular death, whichever comes first(6 months post randomization)
- Changes in Left Ventricular End Systolic Volume (LVESV) and in Left Ventricular End Diastolic Volume (LVEDV)(6 months post randomization)
- Change in NYHA functional class(6 months post randomization)
- All-cause mortality(6 months post randomization)